ASweetLife Team, Author at ASweetLife

Diamyd-Licensed Technology Cures Type 1 Diabetes in Mice

Researchers at UCLA have confirmed earlier findings that combinations of GABA and Antigen Based Therapy (ABT) works synergistically as a treatment in the NOD mouse model of type 1 diabetes. Diamyd Medical is the exclusive licensee for the commercialization of UCLA's GABA technology for metabolic diseases including in diabetes.

Healthy Teeth and Gums Lead to Lower Health Care Costs

People with diabetes are at greater risk of developing gum disease (gingivitis and periodontal disease) than people who do not have diabetes. Gum disease is a bacterial infection in the mouth can cause blood glucose levels to rise. The link is inflammation. The build-up of inflammatory substances in the blood can worsen chronic health conditions.

Add Sunflower Seeds To Your Diet

Sunflower seeds are low carb, nutrient rich, crunchy, nutty-tasting, cute, and versatile. You can sprinkle them on yogurt, cold cereal and granola, salads, and even scrambled eggs. You can also add them to soup, muffins,grind them into flour or into a sunflower seed paste.

FDA Approves First Test For Diagnosing Type 1 Diabetes

The U.S. FDA has allowed marketing of the first zinc transporter 8 autoantibody (ZnT8Ab) test that can help determine if a person has type 1 diabetes and not another type of diabetes. When used with other tests and patient clinical information, the test may help some people with type 1 diabetes receive timely diagnosis and treatment for their disease. Early treatment of type 1 diabetes is important in helping to prevent further deterioration of insulin producing cells.

FDA Grants Tentative Approval to Lilly’s New Insulin Glargine Injection Basaglar

The U.S. FDA has granted tentative approval for Basaglar (insulin glargine injection). With a tentative approval, the FDA has determined that…

Sanofi Licenses Afrezza Inhaled Insulin from MannKind

Sanofi and MannKind Corporation have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin

FDA Accepts Sanofi’s NDA for New Basal Insulin, Toujeo

The U.S. Food and Drug Administration (FDA) has accepted for review Sanofi’s New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for EU countries on May 27, 2014.

FDA Approves Afrezza Rapid-Acting Inhaled Insulin

The U.S. FDA approved Mannkind Corporation's Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin, to improve glycemic control in adults with diabetes mellitus. Afrezza is administered at the beginning of each meal, or within 20 minutes after starting a meal.

iHealth to Launch iHealth Align: World’s Smallest Mobile Glucose Meter

iHealth Lab Inc. has announced the launch of the iHealth Align, the world’s smallest, FDA-approved mobile blood glucose monitor. The meter plugs directly into a smart phone and displays and stores readings using the iHealth Gluco-Smart app...

Dexcom G4 PLATINUM Professional Continuous Glucose Monitoring System Receives FDA Approval

The U.S. Food and Drug Administration (FDA) has given its approval for the Dexcom G4 PLATINUM Professional continuous glucose monitoring system (CGM). The Dexcom G4 PLATINUM Professional is the only professional-version CGM that offers real-time, unblinded feedback allowing the patient to experience the full benefits of real-time CGM...